QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.107.126110v1 323/2/658    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Hofmann, P. A. Articles by Lothstein, L. Search for Related Content PubMed PubMed Citation Articles by Hofmann, P. A. Articles by Lothstein, L. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB DOXORUBICIN

CARDIOVASCULAR

N-Benzyladriamycin-14-valerate (AD 198): A Non-Cardiotoxic Anthracycline That Is Cardioprotective through PKC- Activation

Departments of Physiology (P.A.H.) and Pharmacology (M.I., Y.K., A.J., T.W.S., L.L.) and the University of Tennessee Cancer Institute (T.W.S., L.L.), the University of Tennessee Health Science Center, Memphis, Tennessee; and Environmental and Occupational Health Sciences Institute, Robert Wood Johnson Medical School, Piscataway, New Jersey (J.L., J.G.)

N-Benzyladriamycin-14-valerate (AD 198) is one of several novel anthracycline protein kinase C (PKC)-activating agents developed in our laboratories that demonstrates cytotoxic superiority over doxorubicin (Adriamycin; DOX) through its circumvention of multiple mechanisms of drug resistance. This characteristic is attributed at least partly to the principal cellular action of AD 198: PKC activation through binding to the C1b (diacylglycerol binding) regulatory domain. A significant dose-limiting effect of DOX is chronic, dose-dependent, and often irreversible cardiotoxicity ascribed to the generation of reactive oxygen species (ROS) from the semiquinone ring structure of DOX. Despite the incorporation of the same ring structure in AD 198, we hypothesized that AD 198 might also be cardioprotective through its ability to activate PKC-, a key component of protective ischemic preconditioning in cardiomyocytes. Chronic administration of fractional LD₅₀ doses of DOX and AD 198 to mice results in histological evidence of dose-dependent ventricular damage by DOX but is largely absent from AD 198-treated mice. The absence of significant cardiotoxicity with AD 198 occurs despite the equal ability of DOX and AD 198 to generate ROS in primary mouse cardiomyocytes. Excised rodent hearts perfused with AD 198 prior to hypoxia induced by vascular occlusion are protected from functional impairment to an extent comparable to preconditioning ischemia. AD 198-mediated cardioprotection correlates with increased PKC- activation and is inhibited in hearts from PKC- knockout mice. These results suggest that, despite ROS production, the net cardiac effect of AD 198 is protection through activation of PKC-.

Address correspondence to: Dr. Leonard Lothstein, Department of Pharmacology, The University of Tennessee Health Science Center, 874 Union Avenue, Memphis, TN 38163. E-mail: llothstein{at}utmem.edu